1st Quarter - Report

INVARIANT LLC for ELI LILLY AND COMPANY

Firm
Client
Income
$20,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Medical/Disease Research/Clinical Labs MED

H.R. 5629, Pathway for Biosimilars Act; H.R. 1038/S. 623, Access to Life-Saving Medicine Act; H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007; S. 1505, Affordable Biologics for Consumers Act; S. 1695, Biologics Price Competition and Innovation Act of 2007, as they pertain to the term of data exclusivity for biologic drugs.

LobbyistCovered position, as disclosed
JULIAN A HAYWOOD Legislative Assistant, Rep. Julian Dixon
HEATHER PODESTA Research Assistant, Congressional Budget Office
STACY STORDAHL Sr Policy Advisor, Senate Comm on Aging

Bills named: S. 623 (110th), S. 1505 (110th), H.R. 5629 (110th), S. 1695 (110th), H.R. 1038 (110th), H.R. 1956 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.